Navigation Links
Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Mar 19, 2007 - Acorda Therapeutics (Nasdaq: ACOR) today announced that Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester, will present data from Acorda's MS-F203 Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at the upcoming American Academy of Neurology (AAN) meeting. The platform presentation will take place on Wednesday May 2, 2007 at 4:15 pm Eastern Time (ET). This abstract was also selected to be part of the Scientific Highlights program, which spotlights the top five percent of the more than 1600 abstracts accepted for presentation at this meeting. The AAN meeting will take place at the Hynes Convention Center in Boston, MA.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeut
'"/>




Page: 1 2

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
3. Acorda Therapeutics to Host Analyst and Investor Reception
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:5/28/2015)... AlloSource ®, one of the ... and soft-tissue allografts for use in surgical procedures ... announced that AlloWrap® DS, its double-sided human amniotic ... reimbursement category. "Reimbursement helps ensure ... said Kimberly French , Director of Marketing ...
(Date:5/28/2015)... 28, 2015 Research ... addition of the  "North America Ultrasound Devices ... - 2019)"  report to their offering.  ... is a type of imaging. It uses ... parts and structures inside the body. Health ...
(Date:5/28/2015)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... the Jefferies 2015 Healthcare Conference on Wednesday, June 3, ... New York .  Lexicon management will provide an ... A webcast of the presentation will be available ... version of the presentation will be available at ...
Breaking Medicine Technology:AlloSource Announces Milestone In Reimbursement For AlloWrap DS 2North America Ultrasound Devices Market Report 2014-2019 - Technology and Applications 2Lexicon To Present At The Jefferies 2015 Healthcare Conference 2
... Suffering from these Diseases, LOS ANGELES, March ... are two serious and debilitating,diseases with no confirmed ... new comprehensive literature study propose a simplified,treatment process ... these diseases., Kent Holtorf, M.D., medical director ...
... Data Presented at SIR Meeting Indicates New Catheter-based, ... Care for Treating Acute DVT, WASHINGTON, March ... the Society of Interventional Radiology,s 33rd Annual,Scientific Meeting ... from Bacchus Vascular, Inc. (Santa Clara, CA) successfully,breaks ...
Cached Medicine Technology:Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia 2Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia 3Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients 2
(Date:5/28/2015)... (PRWEB) May 28, 2015 Dr. ... announced an exclusive deal to patients looking to undergo ... 1 through 30, patients will be able to get ... procedure, for just $600. For a three-treatment package, which ... treatment at no cost. , Dr. Juanita Jenyons, M.D., ...
(Date:5/28/2015)... 28, 2015 Are policies that spell ... hospital stay triggering financial pain for seniors? That’s what ... of Managed Care set to figure out, and its ... rule change. , The study, “Observation Encounters and Subsequent ... MD, MPH, examined how Medicare policies that distinguish between ...
(Date:5/28/2015)... 28, 2015 As the summer approaches, many ... cool. It’s important to make safety a top priority, however, ... swimming tips. , According to the Centers for Disease Control, ... States, not including boating incidents. Additionally, the National Safety Council ... ages 1 to 4. , Amica is sharing the ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Boston Celtics ... wife Beth, both Genesis Foundation Board of Directors members, ... Havlicek Celebrity Fishing Tournament June 4-7. For the past ... event benefitting The Genesis Foundation for children by bringing ... , The 34th John Havlicek Celebrity Fishing Tournament ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The CEO ... announced a just launched blog series which provides analysis ... Hosted on the “R. Bruce Dalglish” profile on Blogger.com, ... R. Bruce Dalglish’s corporate experience. , “Throughout my ... workplace cultures have upon the overall success of businesses,” ...
Breaking Medicine News(10 mins):Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 3Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 3Health News:Splash! Amica Shares 6 Swimming Safety Tips 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2
... A new fitness campaign for older Americans has been introduced by ... meant to encourage people 50 and older to become and stay ... for maintaining health and independence as people age, but regular physical ... to 64; 25 percent of those aged 65 to 74; and ...
... dementia have in common? Perhaps more than meets the eye, ... A diverse group of scientists experts in ... to study drugs that show promise in the treatment of ... heart failure. In this case, the connection between the head ...
... Wayne State University,s Parent Health Lab in the School ... identifies women at risk for drug use by evaluating ... itself. In phase I testing, this new screener proved ... detecting recent drug use. The team of researchers also ...
... in Spanish . Functional psychosis ... patient, thanks to affective symptomatology. Depressive moods, hyperactivity and ... themselves during the first psychotic episodes, and the presence ... differentiating, at an early stage, between the different variations ...
... COLUMBUS, Ohio Researchers at Ohio State University Medical Center ... to deliver a gene into the eyes of people born ... males. , The vector is part of a clinical ... a disease that affects an estimated 100,000 people worldwide. The ...
... Arbor, Mich. -- A University of Michigan Health System laboratory ... cells that could lead to a new treatment for those ... mice, appears in this week,s early edition of the ... promise for preventing the painful episodes and organ damage that ...
Cached Medicine News:Health News:Older Americans Encouraged to Get Fit 2Health News:Scientists explore whether what heals the head can also heal the heart 2Health News:Scientists explore whether what heals the head can also heal the heart 3Health News:Wayne State creating computer-based drug intervention for at-risk post-partum women 2Health News:Precise early diagnosis of psychotic disorders possible 2Health News:Ohio State researchers design a viral vector to treat a genetic form of blindness 2Health News:Researchers reveal potential treatment for sickle cell disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: